- Home
- ECCC vs SNN Comparison
ECCC vs SNN Comparison
Compare ECCC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECCC
- SNN
- Stock Information
- Founded
- ECCC N/A
- SNN 1856
- Country
- ECCC United States
- SNN United Kingdom
- Employees
- ECCC N/A
- SNN N/A
- Industry
- ECCC Trusts Except Educational Religious and Charitable
- SNN Industrial Specialties
- Sector
- ECCC Finance
- SNN Health Care
- Exchange
- ECCC Nasdaq
- SNN Nasdaq
- Market Cap
- ECCC N/A
- SNN 12.4B
- IPO Year
- ECCC N/A
- SNN 1999
- Fundamental
- Price
- ECCC $23.22
- SNN $29.38
- Analyst Decision
- ECCC
- SNN Strong Buy
- Analyst Count
- ECCC 0
- SNN 1
- Target Price
- ECCC N/A
- SNN N/A
- AVG Volume (30 Days)
- ECCC N/A
- SNN 683.3K
- Earning Date
- ECCC N/A
- SNN 08-01-2024
- Dividend Yield
- ECCC N/A
- SNN 2.55%
- EPS Growth
- ECCC N/A
- SNN 39.77
- EPS
- ECCC N/A
- SNN 0.35
- Revenue
- ECCC N/A
- SNN $5,642,000,000.00
- Revenue This Year
- ECCC N/A
- SNN $6.92
- Revenue Next Year
- ECCC N/A
- SNN $5.43
- P/E Ratio
- ECCC N/A
- SNN $41.81
- Revenue Growth
- ECCC N/A
- SNN 5.48
- 52 Week Low
- ECCC N/A
- SNN $21.53
- 52 Week High
- ECCC N/A
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- ECCC 48.51
- SNN 45.92
- Support Level
- ECCC $23.14
- SNN $28.26
- Resistance Level
- ECCC $23.50
- SNN $29.64
- Average True Range (ATR)
- ECCC 0.19
- SNN 0.37
- MACD
- ECCC -0.05
- SNN 0.02
- Stochastic Oscillator
- ECCC 25.99
- SNN 48.33
About ECCC Eagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031
Eagle Point Credit Co Inc is an externally managed, non-diversified closed-end management investment company.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.